Education

Ph.D, West Virginia University, USA, 2004

Current position

Assistant Professor, Pharmaceutics & Pharmaceutical Chemistry, The Ohio State University, USA

Publications (since 2013)

1. Huang, K. M., Hu, S. and Sparreboom, A. (2018). Drug transporters and anthracycline-induced cardiotoxicity. Pharmacogenomics 19(11): 883-888.
2. Hu, S. and Sprowl, J. A. (2018). Strategies to Reduce Solute Carrier-Mediated Toxicity. Clin Pharmacol Ther
3. Fu, Q., Chen, M., Hu, S., McElroy, C. A., Mathijssen, R. H., Sparreboom, A. and Baker, S. D. (2018). Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 1090: 43-51. 
4. Drenberg, C., Shelat, A., J. Orwick, S., Li, M., Jeon, J. Y., Pioso, M., Buelow, D., Hu, S., Inaba, H., Ribeiro, R., E. Rubnitz, J., Gruber, T., Guy, K. and Baker, S. (2018). Integrated High-Throughput Screen to Identify Novel Treatment Leads for Pediatric Acute Myeloid Leukemia. Cancer Cell (submitted)
5. Leblanc, A. F., Sprowl, J. A., Alberti, P., Chiorazzi, A., Arnold, W. D., Gibson, A. A., Hong, K. W., Pioso, M. S., Chen, M., Huang, K. M., Chodisetty, V., Costa, O., Florea, T., de Bruijn, P., Mathijssen, R. H., Reinbolt, R. E., Lustberg, M. B., Sucheston-Campbell, L. E., Cavaletti, G., Sparreboom, A. and Hu, S. (2018). OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. J Clin Invest 128(2): 816-825. 
6. Hu, S., Leblanc, A. F., Gibson, A. A., Hong, K. W., Kim, J. Y., Janke, L. J., Li, L., Vasilyeva, A., Finkelstein, D. B., Sprowl, J. A., Sweet, D. H., Schlatter, E., Ciarimboli, G., Schellens, J., Baker, S. D., Pabla, N. and Sparreboom, A. (2017). Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity. Clin Transl Sci 10(5): 412-420. 
7. Bins, S., van Doorn, L., Phelps, M. A., Gibson, A. A., Hu, S., Li, L., Vasilyeva, A., Du, G., Hamberg, P., Eskens, F., de Bruijn, P., Sparreboom, A., Mathijssen, R. and Baker, S. D. (2017). Influence of OATP1B1 Function on the Disposition of Sorafenib-beta-D-Glucuronide. Clin Transl Sci 10(4): 271-279. 
8. Drenberg, C. D., Gibson, A. A., Pounds, S. B., Shi, L., Rhinehart, D. P., Li, L., Hu, S., Du, G., Nies, A. T., Schwab, M., Pabla, N., Blum, W., Gruber, T. A., Baker, S. D. and Sparreboom, A. (2017). OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Res 77(8): 2102-2111. 
9. Drenberg, C. D., Buaboonnam, J., Orwick, S. J., Hu, S., Li, L., Fan, Y., Shelat, A. A., Guy, R. K., Rubnitz, J. and Baker, S. D. (2016). Evaluation of artemisinins for the treatment of acute myeloid leukemia. Cancer Chemother Pharmacol 77(6): 1231-1243. 
10. Sprowl, J. A., Ong, S. S., Gibson, A. A., Hu, S., Du, G., Lin, W., Li, L., Bharill, S., Ness, R. A., Stecula, A., Offer, S. M., Diasio, R. B., Nies, A. T., Schwab, M., Cavaletti, G., Schlatter, E., Ciarimboli, G., Schellens, J. H., Isacoff, E. Y., Sali, A., Chen, T., Baker, S. D., Sparreboom, A. and Pabla, N. (2016). A phosphotyrosine switch regulates organic cation transporters. Nat Commun 7: 10880.
11. Drenberg, C. D., Hu, S., Li, L., Buelow, D. R., Orwick, S. J., Gibson, A. A., Schuetz, J. D., Sparreboom, A. and Baker, S. D. (2016). ABCC4 Is a Determinant of Cytarabine-Induced Cytotoxicity and Myelosuppression. Clin Transl Sci 9(1): 51-59. 
12. Drenberg, C. D., Paugh, S. W., Pounds, S. B., Shi, L., Orwick, S. J., Li, L., Hu, S., Gibson, A. A., Ribeiro, R. C., Rubnitz, J. E., Evans, W. E., Sparreboom, A. and Baker, S. D. (2016). Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Clin Pharmacol Ther 99(6): 651-660. 
13. Zimmerman, E. I., Gibson, A. A., Hu, S., Vasilyeva, A., Orwick, S. J., Du, G., Mascara, G. P., Ong, S. S., Chen, T., Vogel, P., Inaba, H., Maitland, M. L., Sparreboom, A. and Baker, S. D. (2016). Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death. Cancer Res 76(1): 117-126. 
14. Vasilyeva, A., Durmus, S., Li, L., Wagenaar, E., Hu, S., Gibson, A. A., Panetta, J. C., Mani, S., Sparreboom, A., Baker, S. D. and Schinkel, A. H. (2015). Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b. Cancer Res 75(13): 2729-2736. 
15. Pabla, N., Gibson, A. A., Buege, M., Ong, S. S., Li, L., Hu, S., Du, G., Sprowl, J. A., Vasilyeva, A., Janke, L. J., Schlatter, E., Chen, T., Ciarimboli, G. and Sparreboom, A. (2015). Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. Proc Natl Acad Sci U S A 112(16): 5231-5236. 
16. Nieuweboer, A. J., Hu, S., Gui, C., Hagenbuch, B., Ghobadi Moghaddam-Helmantel, I. M., Gibson, A. A., de Bruijn, P., Mathijssen, R. H. and Sparreboom, A. (2014). Influence of drug formulation on OATP1B-mediated transport of paclitaxel. Cancer Res 74(11): 3137-3145. 
17. Hu, S., Mathijssen, R. H., de Bruijn, P., Baker, S. D. and Sparreboom, A. (2014). Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Br J Cancer 110(4): 894-898. 
18. Nies, A. T., Schaeffeler, E., van der Kuip, H., Cascorbi, I., Bruhn, O., Kneba, M., Pott, C., Hofmann, U., Volk, C., Hu, S., Baker, S. D., Sparreboom, A., Ruth, P., Koepsell, H. and Schwab, M. (2014). Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). Clin Cancer Res 20(4): 985-994. 
19. Zimmerman, E. I., Turner, D. C., Buaboonnam, J., Hu, S., Orwick, S., Roberts, M. S., Janke, L. J., Ramachandran, A., Stewart, C. F., Inaba, H. and Baker, S. D. (2013). Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood 122(22): 3607-3615. 
20. Furmanski, B. D., Hu, S., Fujita, K. I., Li, L., Gibson, A. A., Janke, L. J., Williams, R. T., Schuetz, J. D., Sparreboom, A. and Baker, S. D. (2013). Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib. Clin Cancer Res 19(16): 4359-4370. 
21. Sprowl, J. A., van Doorn, L., Hu, S., van Gerven, L., de Bruijn, P., Li, L., Gibson, A. A., Mathijssen, R. H. and Sparreboom, A. (2013). Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. Clin Pharmacol Ther 94(5): 585-592. 
22. Lancaster, C. S., Sprowl, J. A., Walker, A. L., Hu, S., Gibson, A. A. and Sparreboom, A. (2013). Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics. Mol Cancer Ther 12(8): 1537-1544. 
23. Zimmerman, E. I., Hu, S., Roberts, J. L., Gibson, A. A., Orwick, S. J., Li, L., Sparreboom, A. and Baker, S. D. (2013). Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res 19(6): 1458-1466.
24. Navid, F., Baker, S. D., McCarville, M. B., Stewart, C. F., Billups, C. A., Wu, J., Davidoff, A. M., Spunt, S. L., Furman, W. L., McGregor, L. M., Hu, S., Panetta, J. C., Turner, D., Fofana, D., Reddick, W. E., Leung, W. and Santana, V. M. (2013). Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. Clin Cancer Res 19(1): 236-246.